Takeda Pharmaceutical Company Limited Stock Mexican S.E.
Equities
TAK N
US8740602052
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
240.5 MXN | -1.84% | -.--% | +0.33% |
05-16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
05-15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
Sales 2024 | 4,264B 27.16B 453B 36.99B | Sales 2025 * | 4,161B 26.51B 443B 36.1B | Capitalization | 6,481B 41.29B 689B 56.23B |
---|---|---|---|---|---|
Net income 2024 | 144B 918M 15.32B 1.25B | Net income 2025 * | 127B 810M 13.53B 1.1B | EV / Sales 2024 | 1.54 x |
Net Debt 2024 * | 3,771B 24.02B 401B 32.71B | Net Debt 2025 * | 4,125B 26.28B 439B 35.78B | EV / Sales 2025 * | 2.55 x |
P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
48.8
x | Employees | 49,095 |
Yield 2024 * |
4.53% | Yield 2025 * |
4.62% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 day | -1.84% | ||
3 months | -1.84% | ||
6 months | +0.33% | ||
Current year | +0.33% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.51% | 727B | |
+31.97% | 594B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+15.02% | 243B | |
+7.91% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- 4502 Stock
- TAK N Stock